Thrivent Financial for Lutherans’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-71,599	Closed	-$2.66M	–	2557
2023 Q1	$2.66M	Sell	71,599 -61,734	-46%	-$2.78M	0.01%	1109
2022 Q4	$6.04M	Buy	+133,333	New	+$8.63M	0.02%	738
2021 Q2	–	Sell	-4,495	Closed	-$770K	–	2542
2021 Q1	$770K	Sell	4,495 -688	-13%	-$136K	﹤0.01%	2023
2020 Q4	$1.14M	Buy	5,183 +49	+1%	+$10.6K	﹤0.01%	1664
2020 Q3	$853K	Buy	5,134 +1,419	+38%	+$194K	﹤0.01%	1663
2020 Q2	$424K	Hold	3,715	–	–	﹤0.01%	1976
2020 Q1	$286K	Buy	+3,715	New	+$333K	﹤0.01%	1995

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Thrivent Financial for Lutherans's MRTX Position: Q2 2023 in Review

Thrivent Financial for Lutherans sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 71,599 shares — an estimated $2.66M sold.

Thrivent Financial for Lutherans first reported a position in MRTX in Q1 2020 and held it in 7 quarters. The position peaked at $6.04M in Q4 2022. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

Thrivent Financial for Lutherans reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Thrivent Financial for Lutherans sold 71,599 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $2.66M.
Thrivent Financial for Lutherans first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2020 and held it in 7 quarters.
Thrivent Financial for Lutherans's Mirati Therapeutics, Inc. Common Stock position peaked at $6.04M in Q4 2022.
207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2023, filed 14 Aug 2023.